The industry is readying for a leap into a new age of complex therapies. Elaborate manufacturing and soaring drug costs, however, loom as deep chasms to cross in bridging the potential with reality. Casey McDonald reports.
... /Read more/
Advertisement
Read this Front & Center article to see how your Hub can be a Secret Weapon to improve Outcomes. Learn more
The surprise victory of Donald Trump opens the door to new strategies for providing healthcare to Americans, including coverage and oversight of prescription drugs.
... /Read more/
Biopharma companies are increasingly leveraging product portfolios to own and dominate strategically important therapeutic areas, writes Stan Bernard.
... /Read more/
Loss of exclusivity (LOE) doesn't have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
... /Read more/
